Purpose of review: Recipients of solid organ transplants (SOTs) suffer a significant burden of invasive fungal infections (IFIs). The emergence of drug-resistant fungi and toxicities of currently used antifungal agents as well as drug-drug interactions with immunosuppressants make their treatment challenging. This review discusses selected novel antifungal agents in the development pipeline that can currently be used through clinical trials or may be commercially available in the near future.
Recent findings: These agents in development have novel pharmacokinetics and pharmacodynamics, expanded spectra of activity and excellent safety profiles.
Summary: The properties of novel antifungal agents have the potential to expand the therapeutic options for IFIs in recipients of SOTs.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.